Guardian Pharmacy Services Q2 Earnings Call Highlights

Key Points

• Guardian reported solid Q2 operating growth: Revenue rose 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million. Gross profit climbed 18% and net income rose to $22.1 million, helped in part by an $8.5 million payer-dispute settlement.
• The company raised its 2026 outlook to revenue of $1.43 billion–$1.45 billion and adjusted EBITDA of $129 million–$131 million, citing strong underlying growth despite continued Inflation Reduction Act pricing pressure.
• Guardian is expanding through acquisitions, new pharmacy locations and clinical programs, while strengthening its leadership structure. The company ended the quarter with nearly $90 million in cash and remains focused on acquisitions and greenfield investments.

Guardian Pharmacy Services NYSE: GRDN reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.

Chief Executive Officer Fred Burke said first-half reported revenue rose 2%, but would have increased by a low-double-digit percentage without IRA pricing reductions. Adjusted EBITDA for the first half increased 23% from the year-earlier period, according to the company.

Based on first-half performance and expectations for the rest of the year, Guardian raised its 2026 outlook. The company now expects revenue of $1.43 billion to $1.45 billion, compared with its prior range of $1.40 billion to $1.42 billion. It raised projected adjusted EBITDA to $129 million to $131 million from $123 million to $127 million.

Margin gains and IRA impact

Chief Financial Officer Will Mudd said revenue in the quarter benefited from organic growth, acquisitions, higher resident acuity, plan optimization efforts, and favorable product and payer mix. Residents served at quarter-end exceeded 210,000, increasing by a high-single-digit percentage year over year, while prescription volumes also rose by a high-single-digit percentage.

Gross profit rose 18% to $80 million, resulting in a gross margin of 22.8%, despite higher fuel costs. Selling, general and administrative expenses were $56.5 million, or 16.9% of revenue.

Guardian recorded net income of $22.1 million, compared with $8.8 million in the prior-year quarter. The quarter’s net income included an $8.5 million cash payment from the settlement of a payer dispute, which was recorded as other income and excluded from adjusted EBITDA because the company said it was not representative of ongoing operating performance.

Mudd said acquisitions and greenfield locations launched in 2024 and 2025 remained below Guardian’s corporate margin and reduced consolidated margin by roughly 60 basis points in the second quarter. That was an improvement from an estimated 80-basis-point impact in the first quarter.

For the second half, the company expects reported revenue to decline year over year by a low-single-digit percentage because of continued IRA-related pricing reductions. Excluding those reductions, underlying revenue growth is expected to remain in the high-single digits. Guardian expects adjusted EBITDA margin to be relatively stable in the third quarter and to increase seasonally in the fourth quarter due to vaccine activity.

Burke said the next tranche of IRA pricing reductions is expected to have a smaller revenue effect than the 2026 tranche. He said the company expects the next group to represent roughly 40% of the 2026 tranche, though the estimate has not been definitively analyzed because the specific drugs have not yet been identified. He added that Guardian is comfortable it has mitigated the margin impact on EBITDA.

Expansion initiatives and clinical programs

Chief Operating Officer David Morris said Guardian’s clinicians served more than 300,000 residents in the first half of 2026 and completed more than 50,000 clinical interventions affecting more than 45,000 residents. Those interventions included identifying approximately 4,000 allergy risks and 5,000 potential duplicate drug therapies.

The company is also expanding its Falls Risk Program to additional facilities for further evaluation. Morris said early data showed meaningful improvements in outcomes, although he noted the sample size remains relatively small.

Guardian announced after the end of the quarter that it acquired Wellness Concepts, a long-term care pharmacy in Virginia’s Shenandoah Valley. Morris described the business as smaller in size but consistent with the types of service-oriented pharmacies Guardian seeks to add to its platform.

The company also opened a greenfield pharmacy in Lexington, Kentucky, its first location in the state. Morris said the site is supported by Guardian’s Tennessee and Cincinnati pharmacies and illustrates the company’s approach to expanding into contiguous markets where it already serves business from nearby operations.

Burke said the company generally expects it to take roughly four years for new acquisitions and greenfield locations to reach corporate-average profitability, though individual locations may progress faster or take longer depending on their circumstances.

Leadership changes and capital allocation

Guardian appointed Morris as COO after he had served as CFO since the company’s inception. Mudd, who joined Guardian in 2012 and had worked with Morris for more than a decade, succeeded him as CFO.

The company also established a regional leadership structure, appointing eight internal senior vice presidents to oversee its national footprint. Morris said the leaders are expected to provide greater consistency, accountability and support for local pharmacies while maintaining local decision-making and the company’s entrepreneurial culture.

Guardian ended the quarter with nearly $90 million in cash, up from about $65 million in the prior quarter. Mudd said cash conversion returned to a more normalized level after a one-time working-capital reset related to IRA implementation in the first quarter.

Burke said the company’s primary capital-allocation focus remains acquisitions and greenfield startups. He said Guardian also intends to retain financial flexibility while it monitors potential opportunities involving Omnicare assets, though no impact from such opportunities is included in the company’s guidance.

Burke also said the final tranche of Class B common stock is expected to convert into Class A common stock in late September, representing approximately 13.5 million shares. Following the conversion, the company expects employees, management and directors collectively to hold between 35 million and 37 million Class A shares, with nearly all subject to closed-window trading restrictions until the next open trading window following third-quarter earnings.

About Guardian Pharmacy Services (NYSE:GRDN)

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source